Roughly 168,000 veterans receiving care have Alzheimer’s dementia
By Joseph Walker – The Wall Street journal
Eisai Co.’s new Alzheimer’s disease drug Leqembi will be covered by the U.S. Department of Veterans Affairs, the first major insurer to agree to pay for the drug since its approval by U.S. regulators earlier this year. Eisai said Monday veterans with the early stages of Alzheimer’s would get the drug covered under criteria set by the VA.